Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: oxaliplatin

« Back to Dashboard
Oxaliplatin is the generic ingredient in two branded drugs marketed by Sanofi Aventis Us, Actavis Totowa, Ebewe Pharma, Fresenius Kabi Oncol, Fresenius Kabi Usa, Hospira Inc, Hospira Worldwide, Jiangsu Hengrui Med, Mylan Labs Ltd, Sandoz, Sun Pharma Global, and Teva Pharms, and is included in seventeen NDAs. There are two patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are twenty-six drug master file entries for oxaliplatin. Five suppliers are listed for this compound. There are five tentative approvals for this compound.

Summary for Generic Name: oxaliplatin

Drug Master File Entries: see list26
Suppliers / Packaging: see list11

Pharmacology for Ingredient: oxaliplatin

Tentative approvals for OXALIPLATIN

Applicant Application No. Form Dosage
<disabled><disabled>INJECTABLE; INJECTION5MG/ML
<disabled><disabled>INJECTABLE; INJECTION5MG/ML
<disabled><disabled>INJECTABLE; IV (INFUSION)200MG/40ML

Clinical Trials for: oxaliplatin

Oxaliplatin in Treating Patients With Metastatic Breast Cancer
Status: Active, not recruiting Condition: Stage IV Breast Cancer

Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer
Status: Recruiting Condition: Neurotoxicity

Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer
Status: Completed Condition: Colorectal Cancer

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Status: Terminated Condition: Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Ovarian Mucinous Cystadenocarcinoma; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Gastric Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Pancreatic Cancer; Recurrent Rectal Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Gastric Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Pancreatic Cancer; Stage IV Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific

Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
Status: Completed Condition: Hepatoma; Advanced Solid Tumor

Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
Status: Active, not recruiting Condition: Advanced Cancers

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Jiangsu Hengrui Med
INJECTABLE;IV (INFUSION)203869-002Jun 18, 2014RXNo<disabled><disabled>
Mylan Labs Ltd
INJECTABLE;IV (INFUSION)200979-002Aug 8, 2012RXNo<disabled><disabled>
Sun Pharma Global
INJECTABLE;IV (INFUSION)078818-002Aug 7, 2009RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn